Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

<p>Cluster defining genes from scRNAseq data</p>

Uloženo v:

Podrobná bibliografie
Hlavní autor:	Isha Mondal (16721699) (author)
Další autoři:	Oishika Das (16721702) (author), Raymond Sun (16721705) (author), Jian Gao (16721708) (author), Bohyeon Yu (16721711) (author), Aaron Diaz (16721714) (author), Jinan Behnan (16721717) (author), Abhishek Dubey (16721720) (author), Zhipeng Meng (16721723) (author), Emad Eskandar (16721726) (author), Beisi Xu (14941098) (author), Rongze Olivia Lu (16721729) (author), Winson S. Ho (16721732) (author)
Vydáno:	2025
Témata:	Cancer Tumor Biology Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Immune responses to cancer Immunotherapy Combination immunotherapy Tumor Microenvironment Immune cells and the microenvironment
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Autor: Min Wu (14962986)
Vydáno: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Autor: Andrew O. Yam (15293045)
Vydáno: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Autor: Francisco Hermida-Prado (14958909)
Vydáno: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Autor: Michael Kilian (16697663)
Vydáno: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Autor: Michael Kilian (16697663)
Vydáno: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Autor: Michael Kilian (16697663)
Vydáno: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Autor: Axel Stenmark Tullberg (15029928)
Vydáno: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Autor: Andrew Nguyen (17142197)
Vydáno: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Autor: Li-Li Long (14963775)
Vydáno: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
Autor: Kankan Cao (16437263)
Vydáno: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Autor: Carlotta Antoniotti (15352506)
Vydáno: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Autor: Carlotta Antoniotti (15352506)
Vydáno: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Autor: Carlotta Antoniotti (15352506)
Vydáno: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Autor: Clare Vesely (505402)
Vydáno: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Autor: Erika Y. Faraoni (14844897)
Vydáno: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Autor: Maria Lozano-Rabella (15056515)
Vydáno: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Autor: Maria Lozano-Rabella (15056515)
Vydáno: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Autor: Maria Lozano-Rabella (15056515)
Vydáno: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n8v86ne6l59f030crbdi5uj4kr